ClinicalTrials.govpublic full text
CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML
high risk acute myeloid leukemia, allogeneic hematopoeitic stem cell transplantation, cladribine, fludarabine, relapse, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 810479
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.